Lamivudine treatment for severe acute HBV hepatitis

International Journal of Medical Sciences

Volumn 5, Issue 6, 2008, Pages 309-312

  Lisotti, Andrea ^a   Azzaroli, Francesco ^a   Buonfiglioli, Federica ^a   Montagnani, Marco ^a   Alessandrelli, Flavio ^a   Mazzella, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute HBV hepatitis; Fulminant hepatitis; Lamivudine; Recovery; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE;

EID: 54949119174     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.309     Document Type: Article

References (11)

1. Zanetti AR, Romano L, Zappa A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol 2006;36(Suppl 1): S51-5
2. Mele A, Spada E, Sagliocca L, Ragni P, Tosti ME, Gallo G, Moiraghi A, Balocchini E, Sangalli M, Lopalco PL Stroffoli T. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol 2001;35: 284-9
3. Schreiber GB, Busch MP, Kleinman SH Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334: 1685-90
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144: 705-14
5. Hoofnagle JH, Doo E, Liang TJ, Fleischer R Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45: 1056-75
6. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M Hadziyannis SJ. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat 1997;4: 387-94
7. Torii N, Hasegawa K, Ogawa M, Hashimo E Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002;24: 34
8. Kondili LA, Osman H Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004;11: 427-31
9. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, Safadi R, Lurie Y, Rosner G, Tur-Kaspa R Reshef R. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24: 547-51
10. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13(4):256-63.
11. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC Sarin SK. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45: 97-101